Trial Profile
The diagnosis of pleuroperitoneal communication by contrast enhanced ultrasonography with perflubutane
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Perflubutane (Primary)
- Indications Ascites; Pleural disorders
- Focus Diagnostic use
- 30 Jan 2015 New trial record